key: cord-0734233-g2vna5db authors: Sullivan, Frank M.; Tello, Agnes; Rauchhaus, Petra; Santiago, Virginia Hernandez; Daly, Fergus title: Assessment of background levels of autoantibodies as a prognostic marker for severe SARS-CoV-2 infection date: 2022-05-03 journal: J Circ Biomark DOI: 10.33393/jcb.2022.2337 sha: f36ef7b3e813e093a09e043fdd9c745124322d2e doc_id: 734233 cord_uid: g2vna5db BACKGROUND: Patients with more severe forms of SARS-CoV-2 exhibit activation of immunological cascades. Participants (current or ex-smokers with at least 20 years pack history) in a trial (Early Diagnosis of Lung Cancer, Scotland [ECLS]) of autoantibody detection to predict lung cancer risk had seven autoantibodies measured 5 years before the pandemic. This study compared the response to Covid infection in study participants who tested positive and negative to antibodies to tumour-associated antigens: p53, NY-ESO-1, CAGE, GBU4-5, HuD, MAGE A4 and SOX2. METHODS: Autoantibody data from the ECLS study was deterministically linked to the EAVE II database, a national, real-time prospective cohort using Scotland’s health data infrastructure, to describe the epidemiology of SARS-CoV-2 infection, patterns of healthcare use and outcomes. The strength of associations was explored using a network algorithm for exact contingency table significance testing by permutation. RESULTS: There were no significant differences discerned between SARS-CoV-2 test results and EarlyCDT-Lung test results (p = 0.734). An additional analysis of intensive care unit (ICU) admissions detected no significant differences between those who tested positive and negative. Subgroup analyses showed no difference in COVID-19 positivity or death rates amongst those diagnosed with chronic obstructive pulmonary disease (COPD) with positive and negative EarlyCDT results. CONCLUSIONS: This hypothesis-generating study demonstrated no clinically valuable or statistically significant associations between EarlyCDT positivity in 2013-15 and the likelihood of SARS-CoV-2 positivity in 2020, ICU admission or death in all participants (current or ex-smokers with at least 20 years pack history) or in those with COPD or lung cancer. Patients infected with Covid-19 show a range of immune responses, from weaker immune responses in asymptomatic individuals, to symptomatic patients showing a varying degree of immune dysregulation. These may be manifested by increased levels of interleukins, C-reactive protein and D-dimer, along with lymphopenia, monocytosis and neutrophilia. Extremely high levels of proinflammatory cytokines can lead to a cytokine storm and macrophage activation © 2022 The Authors. Published by AboutScience -www.aboutscience.eu increasing the detectable signal for the corresponding level of antigen (8) . They persist in the circulation with half-lives of typically up to 30 days (9) . The EarlyCDT-Lung test is an enzyme-linked immunosorbent assay (ELISA) that measures seven autoantibodies, each with individual specificity for the following tumourassociated antigens (TAAs): p53, NY-ESO-1, CAGE, GBU4-5, HuD, MAGE A4 and SOX2 (10) . A sample is positive if at least one autoantibody is elevated above a predetermined cutoff (11) . The test has been developed throughout the preclinical, clinical assay validation and retrospective biomarker development pathway stages. In cohort studies, it has demonstrated a specificity of 91% and sensitivity of 41%. The Early Diagnosis of Lung Cancer Scotland (ECLS) study was a phase IV biomarker trial using EarlyCDT-Lung followed by imaging in 12,208 smokers and ex-smokers aged 50-75 at risk of developing lung cancer recruited from General Practices in Scotland (12, 13) . A total of 6,088 participants in the intervention arm received the EarlyCDT-Lung test at the baseline visit and 598 (9.8%) had a positive autoantibody result. In the 2-year analysis of the ECLS trial, EarlyCDT-Lung was shown to reduce late stage presentations of lung cancer. We have investigated whether the production of autoantibodies in response to cell surface abnormalities in cancer, as measured by the baseline EarlyCDT-Lung test in the ECLS trial, was associated with more severe disease in at-risk participants (current and former smokers) who then developed a SARS-CoV-2 infection 5-6 years later. Participants aged 50-75 who were current or ex-smokers with at least 20 years pack history were recruited to ECLS between December 2013 and April 2015, and all baseline assessments of plasma antibody levels occurred during this time (14) . SARS-CoV-2 status and outcome data for ECLS participants during 2020 were obtained from the EAVE II database, which is a national, real-time prospective cohort using Scotland's health data infrastructure, to describe the epidemiology of SARS-CoV-2 infection, patterns of healthcare use and outcomes (15, 16) . Data from both sources was linked using Scotland's Community Health Index (CHI) number at the University of Dundee's Health Informatics Centre (HIC) (17,18). The strength of associations was explored using a network algorithm for exact contingency table significance testing by permutation. This approach is appropriate for the sparseness of the data here, where an approximate chi-squared analysis would provide severely discrepant outputs. (For 2 × 2 contingency tables, the network algorithm reduces identically to Fisher's exact test.) There were no significant differences discerned between SARS-CoV-2 test results and EarlyCDT-Lung test results (positive/negative) (p = 0.734); or likewise between SARS-CoV-2 test results and EarlyCDT-Lung test results (positive/negative/ control) (p = 0.779); or finally between SARS-CoV-2 test results and Treatment (tested/not tested) (p = 0.587). An additional analysis of intensive care unit (ICU) admissions detected no significant differences between those who tested positive and negative. There was no difference in COVID-19 positivity or death rates amongst those diagnosed with lung cancer with positive and negative EarlyCDT-Lung test results (Tab. I). In Table II , nil significance was found. Table III shows no difference in COVID-19 positivity or death rates amongst those diagnosed with chronic obstructive pulmonary disease (COPD) with positive and negative EarlyCDT results. No clinically valuable or statistically significant associations between EarlyCDT-Lung positivity in 2013-15 and the likelihood of SARS-CoV-2 positivity in 2020, ICU admission or death were found. This was true for the entire study cohort and in subgroup analyses of at-risk participants (current and former smokers) with lung cancer and COPD. This is in contradistinction to those exhibiting the nucleolar immunofluorescence pattern where a significant association with interstitial lung SARS-CoV-2 disease has been demonstrated (19) . Strengths of the study include the community-based sampling of the ECLS cohort, large numbers of the cohort who had a Covid test validated by laboratory and outcome assessment. Weaknesses include the time which had elapsed between the initial trial and the onset of the pandemic, as well as small numbers of study subjects who were in the subgroup analyses. Some studies have shown that some routine clinical laboratory tests, such as lymphocyte count, lactate dehydrogenase and D-dimer are known to be affected in patients with COVID-19 (20) , with lymphopenia, raised lactate dehydrogenase and elevated D-dimer being associated with worse disease severity and outcomes (21-23). Other studies have shown significant differences in inflammatory markers amongst patients who required ICU admission compared to patients who have not, and markers of infection and inflammation such as C-reactive protein, procalcitonin, and ferritin which are, as expected, correlated with severe disease (24) (25) (26) (27) . This hypothesis-generating study did not find a clear association between the expression of tumour-associated antibodies in the ECLS cohort of at-risk participants (all current and former smokers) and the development of SARS-CoV-2 infection and its complications 5 years later. Immune dysregulation and system pathology in COVID-19 Outcomes of COVID-19 related hospitalization among people with HIV in the ISARIC WHO Clinical Characterization Protocol (UK): a prospective observational study Autoantibodies in moderate and critical cases of COVID-19 Autoantibodies neutralizing type I interferons in 20% of COVID-19 deaths in a French hospital COVID-19 and immunological dysregulation: can autoantibodies be useful? Humoral immune mechanisms involved in protective and pathological immunity during COVID-19 Profiling tumor-associated antibodies for early detection Serum and blood based biomarkers for lung cancer screening: a systematic review The sentinel within: exploiting the immune system for cancer biomarkers EarlyCDT-Lung: an immunobiomarker test as an aid to early detection of lung cancer Technical validation of an autoantibody test for lung cancer Phases of biomarker development for early detection of cancer Early Diagnosis of Lung Cancer Scotland (ECLS) Team. Earlier diagnosis of lung cancer in a randomised trial of an autoantibody blood test followed by imaging Detection in blood of autoantibodies to tumour antigens as a case-finding method in lung cancer using the EarlyCDT®-Lung Test (ECLS): study protocol for a randomized controlled trial The Scottish record linkage system Cohort profile: early pandemic evaluation and enhanced surveillance of COVID-19 (EAVE II) database Data Team Linkage Options Antinuclear antibodies in COVID 19 Multicenter analysis of clinical characteristics and outcomes in patients with COVID-19 who develop liver injury Prognostic value of elevated lactate dehydrogenase in patients with COVID-19: a systematic review and meta-analysis D-dimer as a biomarker for assessment of COVID-19 prognosis: d-dimer levels on admission and its role in predicting disease outcome in hospitalized patients with COVID-19 Proteomic and metabolomic characterization of COVID-19 patient sera The role of C-reactive protein in predicting the severity of COVID-19 disease: a systematic review High procalcitonin levels associated with increased intensive care unit admission and mortality in patients with a COVID-19 infection in the emergency department Serum ferritin as a predictive biomarker in COVID-19. A systematic review, meta-analysis and meta-regression analysis This project was funded by The Lung Foundation. The funder had no role in the design, conduct or analysis of the study. The authors have no other financial conflicts to disclose. The authors confirm that all appropriate ethical guidelines for the use of human subjects have been followed and ethics committee review has been obtained. The authors confirm that all necessary patient/participant consent or assent has been obtained, and the appropriate institutional forms have been archived. A version of the article appears as a preprint on ResearchSquare (DOI: 10.21203/rs.3.rs-842075/v1) Institutional approval was provided by the University of St Andrews.